seema mody with the details. seema? >> maria, that's right. a couple stocks on the move.orth taking a look at. let's start with gentex. shares, a company which makes such equipment is down 13%, more than 13% actually. switch over to scientific games. maker of instant lottery tickets posted a surprising loss due to higher expenses. the stock down around 14%. lastly, biotech firm viva, up another 5%. up 5.8% behind their obesity drug. perhaps receiving fda approval which could be a major milestone in the weight loss market. since winning the backing on thursday, the stock has climbed 113%. can you believe it? back to sglu seema, thank you. big moves there. we take a short break. we've got the closing countdown right after this break. after the bell we'll get the global sector, and monetary policy in two exclusive interviews. barclays bob diamond is with us, as well as charles plosser. both joining me in the next hour of the "closing bell." first, take a look at the averages as we approach the final few minutes of trading for the day. we're back in a moment on "closing bell.

that's concerning investors seeing weakness across the board. >> seema, thank you. >> seema, thank you very much. today's "closing bell" exchange, we turn our attention to greece. where else, bailout deal falling apart, riots erupt in the capital city, and lucky julia chatterly of cnbc of europe has been covering the great soap opera that has been going on in athens. what's going on, julia? what's the outlook for the weekend? >> well, we estimate around 5,000 people took to the streets today in protest, chanting things like you're setting us back 50 years, and things like hang the politicians. it actually started quite peacefully but it ended rather violent. the police had to use tear gas to disperse the crowd. the protests were called before the meeting when it was told deeper cuts were going to be put in. more protests called for tomorrow. and again, on sunday, ahead of what was expected to be this key meeting of the politicians in parliament to vote on this reform deal. we heard this afternoon that five cabinet ministers have now resigned. the question we're asking is, will this mea

it was up more than 100% as seema noted earlier. telling me he's very optimistic now that the drug will be officially approved by the fda. says formal approval could happen on april 17th. that's the target date that the ceo is now looking at. calls it clearly a game changer for his company. wouldn't give any sales estimates yet. but an analyst that we had on the "fast money" "halftime report" is looking for about $3 billion in sales. certainly a huge number. really a game changer for a company that has spent hundreds of millions of dollars, guys, in ten years trying to bring qnexa to market. it would be the first diet drug officially approved by the fda since i think 1999. so can't -- just a tremendous story. and he'll be on the "fast money" "halftime report" with us live on monday to expand all this. we look forward to that. >> we sure do. that's what the wap is watching. thanks, scotty. sxc is really hot and wall street knows it. the pharma benefits manager turning in better guidance and given its long streak of double-digit growt

. >> i'm seema mody reporting live from the pharma conference. coming up, we'll take a deep dive into the generic drug market, who the winners and losers are, and how investors are trading the space. here's another question. will the usda guidelines slow it down. here's highlights from our guests on cnbc today. >> it's become clear that hiring has declined. the real question is what it means for the apparels, how quickly will hiring pick up. >> this time of the year, over the past ten years we've seen an uptick in prices as the market switches from winter grade gasoline to summer grade gasoline. cleaner burning gasoline is better for the environment, costs more to produce. at the same time consumption and demand increases as the days get longer. >> in the euro, you haven't seen anyone trying to weaken the euro. i think they're happy to see it go lower if it does. i think it helps the situation over there. and desperately in need of some help. >> romney needs to win michigan, period. this is a neck-and-neck race. i think he's going to throw everyt

seema mody. the next guest is on a hunt for opportunities. let's hit options action and get the trade with brian stutland. brian? >> on the hunt is right. a name that's interesting to me is stone energy. a home-grown american company looking at exploration of getting gas and oil right here in the united states, in the appalachian region, in the gulf of mexico. the stock had a tremendous run in 2011, up 17% or so. 2012 has already been a great year for the stock. i think there's more room to run for here. valuations are still compelling, and with earnings next week, i want to echo a bullish sentiment in the options market. by march, a call. i'll sell a march 32 put against that. net net, the trade only cost a dime here. what i do is allocate cash in case i have to buy the stock below 32. i have all the upside potential above 36. if the earnings come out great, i have the upside, if you look at a one-year chart, it could make a new high on its earnings play. it looks very compelling. this is brian stutland bringing you your energy play and earn

details on that, seema. >> let's do that, bill.ield stocks in this tight range throughout the day, with the winners and losers taking their cues from the earnings report. that continues to be a sign of perhaps a healing in the labor market. taking a pulse of the market, though, the dow currently down five points. we also are going to zone in on technology a little faster than i thought. a lot of these, facebook, of course, creating a pop to the tech ipos, after the filing yesterday afternoon. we have zynga, linkedin, all higher today. we're seeing a lot of strength in retail, target reporting a january same-store sales increase. more than twice what analysts had estimated. gap announcing its january 2012 sales which came in at $833 million, that's also higher than expected. gap ceo glen murray told investors they successfully cleared holiday inventory. and a stronger yen and production disruptions in thailand, a couple of the challenges that sony has been facing this quarter. they reported a net loss at $1.2 million for the quarter

bertha coombs at the nymex. >> thanks, seema.ntioned in the energy pits we are seeing prices still high, but a selloff across the board here in terms of the metals today. copper, the worst performer for the week down 4% on continuing concerns of rising inventories in china and slow demand. gold, a real poppy week where we went from resistance level at the top down to support and then pretty much flat a little to the downside on the week. the currency and gold analyst at citi index says an interesting phenomenon is developing with those high oil prices. the gold-to-oil ratio is coming down. it's now at a 6-week low. and historically he says that has been a bullish sign for global stock prices. over to you, sue. >> thank you so much, bertha. stocks kind of moving sideways right now. markets are waiting for that approval, perhaps, of another bailout package for greece. so how do you invest given all the macro risk out there? let's bring in katie nixon, chief investment officer for private partners at northern trusts. more than $163

let's check out now with seema mody what is happening at the nasdaq. and what else also is making headlines today. seema. >> thanks, mandy. here's what else we're watching at this hour. the transportation department delayed a rule that would have rear cameras on cars and trucks. and james murdoch has stepped down as executive chairman as news corp.'s news international unit. rupert murdoch's son will keep his job as news corp.'s deputy chief operating officer. and general motors take a 7% stake in peugot. the two hope various energies will eventually save them $2 billion a year. back to you. >> thank you very much for that, seema mody. flat screens and flat soda. herb's double disaster time. herb. >> mandy, standing here i feel like i should be demonstrating a sodastream machine, not actually talking about their earnings. >> oh, that was famous, wasn't it? or maybe infamous now when you think about it. >> their numbers actually are pretty good. guidance was pretty good. stock's getting whacked because -- coming back a little bit because the company com

i'm seema mody. another strong day for the nasdaq. upbeat economic data driving the bulls into tech. let's start with one of our tech heavy weights, microsoft. definitely catching the attention of investors. hitting a four-year high in today's trade. another bright spot, some of those recently listed tech ipos showing strength. groupon and linkedin being said they're both overvalued. chip stocks, recovering lost ground after a softer than expected sales outlook for the year. some analysts i spoke to say this morning that the weak forecast, perhaps only a temporary setback. maria and bill? >> seema, thank you very much. we do have almost 18 minutes left in the trading session. time for a quick market stat check on the nasdaq. we're on pace to close at a mul multi-year high right now thanks to the strength in the technology sector. apple back above $500 after the big decline yesterday, which seemed to take the rest of the market with it. seema mentioned, microsoft has been stealing the show today, hitting that four-year high, above $31

seema mody with a look at the after-hours action. >> missing a lot of action in the after-hours, specifically in the sciences and pharmaceuticals reporting. i'll get you all the details right after this. >>> welcome back. lots of movers in the after-hours trading session. let's get back to seema mody. >> a recap of all the after-hour movers today, starting with vertex pharmaceuticals. we saw weakness in pharmaceuticals today. that was the laggard in today's trade. merck and pfizer weighing on the index today. vertex pharmaceuticals moving higher. their main drug treats hepatitis c. that missed estimates, but their profit came in higher. analysts already lowered their estimates due to trend. this isn't a huge surprise. keep in mind two days ago, the fda approved a cystic fibrosis drug. also missing street estimates, came in at 97 cents a share for gilead sciences. it kick started a frenzy in the biotech space. bristol-myers, we can expect investors to discuss gilead's acquisition on the call, some saying there will be more details on the action coming up soon. >> seema mody with the latest the

seema mody to run through some of these names. seema?u take a look at what's behind me, you may think we're talking about the super bowl halftime show where madonna brought the house down. but that's not the case, we're looking at the halftime in america. if you look at the stocks in the s&p 500, 80% of stocks are up. i know what you're thinking, what about greece, the european debt crisis? our markets no doubt have had a volatile ride. but if we step back, these stocks are actually up, not just marginally. chipotle, wind resorts, coach, among others, these are consumer-driven stocks showing a lot of strength as we recover from the recession lows. up better than 500%. another interesting stat, thanks to the research team here at cnbc, 285 companies in the s&p are up more than 400% from their march 2009 low. but the question is, halfway through the recession, can we make our way out of it. and more importantly, do these stocks, we've seen monster moves, and can the momentum ride through going forward, and are these a good bet for the seco

seema and bob, thank you very much.ow, let's bring in jim paulson, chief investment strategist at wells capital management and joins us now. jim, as always, you bring up excellent points. i want to hit the issue of stock valuations because you noted us the s&p 500 expected to come in around $100 of total earnings. every multiple point therefore is worth about 100 points on the index. >> right. >> are you confident we can get the expansion we need to say drive the s&p 500 to 1500? >> well, i think a lot of what's happening here in the rally from late last year's lows is a reversal of the fear that was generated last year. last year we had good earnings, but you had the multiple of p/e started about 15 and ended about 13. and you had a collapse in the valuation with rising earnings. you have a flat market. this year what i think we're seeing is the fear subsiding. we found out we way overreacted, that the u.s. was headed for a recession. it probably wasn't close. and we're finding out that europe is not probably an eminen

seema mody wraps up the after-hours action. charles plosser is with me explaining why he believes the financial crisis for central banks blow the lines and create a moral hazard. he'll explain. stay with us. tdd# 1-800-345-2550 i'm constantly working my screens. tdd# 1-800-345-2550 checking the charts. tdd# 1-800-345-2550 looking for support, tdd# 1-800-345-2550 resistance, breakouts, tdd# 1-800-345-2550 a few other tricks that i'll keep to myself. tdd# 1-800-345-2550 that's how i trade. tdd# 1-800-345-2550 and i do it all with charles schwab, tdd# 1-800-345-2550 because their streetsmart edge platform tdd# 1-800-345-2550 helps me trade quickly, intuitively. tdd# 1-800-345-2550 staying on top of the market is key! tdd# 1-800-345-2550 and the momentum tool, tdd# 1-800-345-2550 it lets me do it at a glance, tdd# 1-800-345-2550 so when things shift, i'm ready. tdd# 1-800-345-2550 then to track the stocks i have my eye on, tdd# 1-800-345-2550 i turn to schwab's high/low ticker. tdd# 1-800-345-2550 so i can spot a potential breakout

i'm seema mody.the nasdaq continues to post gains, technology being one of the best performing sectors today. we've been speaking about apple as well as semiconductor stocks outperforming. chinese adrs, report earnings yesterday, they missed street estimates. on the conference call, the ceo saying their twitter light service will contribute to the top line on the second half of 2012. that's adding momentum to all of these stocks right now. money flying into international chinese stocks. nokia, downgraded by oppenheimer. >> seema, thank you very much. about 16 # minutes left in the trading session here, with the dow above 13,000 for the moment. let's check on the nasdaq. which is pushing its way to its highest close since december of 2000. it was up about 22 points at the hive of the day, up 19 right now. we're getting ever closer to the 3,000 mark on the nasdaq composite, now at 29 # 85. we talked earlier about volatility. the see sawing near break even right now, down just a fraction at 1802. it's b

i'm seema mody. another exciting day following tech here. not only are investors putting money into tech, but corporations paying hefty premiums in their respective industries. oracle buying taleo. aside from that, a slew of earnings to help the tech index. the fourth quarter profits topped wall street estimates. google is developing a home entertainment system. cumberland pharmaceuticals, u.s. regulators approved a patent for a new formulation of its liver drug. shares soaring in today's trade. >> thank you so much, seema. even as the u.s. continues to struggle with its own debt issues, the next guest, scott sperling, co-president of the thomas h.l. partners, his firm one of the oldest and experienced private equity firms. one of the nation's leading bayout fund organizations with more than $22 billion on management. it's good to see you again, scott. thank you so much for joining us. >> good to see you. >> let's talk about what's going on in america and why you are increasingly optimistic here. >> the united states is becoming increasingly

. >>> from the nasdaq market site, i'm seema mody. the norm in 2012, today getting a boost from economic data that came out this morning. take a note of the old school tech names, reaching historic highs. microsoft as mentioned before hit a four-year high this afternoon. dell has the tenth biggest impact on the nasdaq 100. cisco hitting a 52-week high. money definitely flowing into the big tech names. our biggest winner here on the nasdaq 100, that was net app posting strong gains after beating street expectations. >> seema, thank you so much. welcome back to the special edition of the "closing bell" coming to you live from the trading floor of second market. second market provides a trading platform for alternative investments like private companies. and fixed income instruments. the company recorded nearly $9 billion in trades last year. with more than 85,000 participants buying and selling these private companies. the biggest name traded on this platform, of course, has been facebook. it's about to go public. how does the second ma

i'm seema mody. another apple centric day. the nasdaq giving up its gains as shares of apple erased a 3% advance that continues to be a market driver. another stock to keep in mind, juniper networks, up better than 6.5%. some analysts say vendors like juniper should see a recover as carriers increase their spending. let's take a look at the biotech sector. amala norks is on the move. their new diabetes drug now available by prescription in the u.s. amylin shares up 2.5%. >> heading to the close. about 19 minutes left. as seema mentioned, nasdaq's been taking its cues from apple today, off the lows right now. but on pace for its third decline of the month. as apple falls off that lifetime high that we saw earlier in the session. right now, the nasdaq's down 15 points at 2,915. it was down 2,100 at the lows set just moments ago. in yellow flag territory, we're up two points, or 10%, well above that 20 level now. closing above 20 in the last four sessions here. mandy? >> okay, bill. well, oil prices are up over 3% this week. as i

i'm seema mody. let's check out some of the big movers.ping in trade after confirming promising data on their cancer drug. medivation helping the stock reach a three-month high. it's also heating up with the prostate drug on the market. they're moving higher because of a management change. the company is looking to increase patient volumes. guys, back over to you. >> seema, thank you very much. heading toward the close, 20 minutes left. time for a quick stat check on the nasdaq, which has been the leader today. the composite soaring to a six-month high. right now, a gain of 1.25%, or 34 points. it was up as many as 42 at the high of the session. technology has been the leader in this market once again. meanwhile, the fear indicator that the vix pulling back as stocks defy gravity. it's below 19 now, down almost 5%. off the lows of the session at 18.5 right now. maria? >> bill, let's take a look at aetna. profits jumping more than 70% in the fourth quarter. let's talk to aetna and how the company plans to stay ahead of the cur2012. joining

maria and bill, over to you. >> seema, thank you very much.e are heading toward the close with about 35 minutes left in the day. we're watching technology. aren't we all. the nasdaq near that 11-year high, within 100 points of the 3,000 level now. so what's the best way to play it these days. let's start talking numbers. chris is here with us, head of technical analysis. what a juggernaut, the technology sector has been lately. >> if you compare it to the s&p, or the dow transport for the russell 2000, it's the strongest looking chart. if you look at ten years, a lot of memory in the $50 to $60 level. we've rallied there, failed in the past, rallied there, failed in the past. but we're up to the $60 level right now. we would use any weakness in the interim to step in. we think it's one of the stro strongest sectors of the market right now. >> there was a lot of repair work to be done after the crash of the bubble ten years ago. amazing. intel, there's one you're looking at specifically right now. would you like it here? >> the index is the who

maria, back over to you. >> seema, thank you. priceline.com, shares continuing to soar in today's trading session. this on the heels of the better than expected fourth-quarter earnings released last night. revenue jumped at better than 40%. year over year increase of some 77%. oil and gas prices reach enough heights in the united states, can priceline keep this momentum going. joining me now is priceline.com president and ceo jeffery boyd. mr. boyd, thanks so much for your time today. good to have you on the program. >> thank you. >> earnings up 65% from a year ago. what's hinted it? how would you characterize the year? >> it was a great year for the briceline group. i think the most important piece of our business that did well is the international hotel business. we grew very strongly in europe and in new markets, in asia, and in south america. we also had a great year in the united states for the hotel business. >> what is going on in the hotel business would you say, given the fact that there are certainly mixed reviews in te

i'm seema mody. let's resetd the markets for you. where'd the rally go?ook at our major indices, we're trading in negative territory. u.s. stocks, commodities selling off after bernanke dented hopes of a fresh round of monetary stimulus for the economy. another story i want to bring your attention to, the big story in the pharma world. the fda warning that patients taking cholesterol lowering stattens may face a slight increase in risk for diabetes and memory problems. now, stat ents the best selling class of drugs in history brought in an accumulative $130 billion in sales for pfizer alone in the last quarter. in q-4 they brought in $2 billion in sales. the big question is, will these pharma players be financially impacted? analysts i spoke to said they're not changing their ratings or estimates in response to this news. many of them already expect a deceleration in sales given the availability of generic options. it's still considered a headwind being monitored very closely. patients will naturally question if the benefits of being on a statten outweigh

i'll let you guys take it from there. >> seema, thank you very much for the set-up there. biomarin pharmaceutical is one of the dominant players in this space. shares up nearly 42% over the past six months. what is the nothing know sis for rare disease treatments? let's bring in j.j., the biomarin pharmaceuticals ceo. this is a niche area. does it mean less competition or do you feel that some of the big boys, like pfizer, increasingly looking at the rare disease space as well? j.j., can you hear us? >> yes, i can. sorry. it's a pleasure to be here. >> the question is whether or not you, therefore, have less competition because it's a niche area or do you feel that the competition is heating up with bigger companies, like pfizer, looking to get in on this as well? >> yeah, some big pharma companies are definitely starting to be interested in the orphan disease space. but at the same time, there are about five to six orphan diseases in the world. the vast majority of them untreed. we have four products on the market for four different orphan diseases. we have five new molec

>> seema, thank you very much. we're heading to the close. about 19 minutes left here.quick smarcheck on t nasdaq. a fresh 11-year high, on course for its sixth gain in the last seven sessions. up 9 points right now at 2913. it was down 11 at the day's lows around noontime eastern time today. volatility index has popped up, up 3% today. we're at 18 and change. unless it gets back to 20, you're not exactly seeing a yellow flag being waved. the last time it was above 20 was around january the 18th. maria, say hi to my friend warren. >> he's right here with me. tech up better than 11%. as far as the s&p technology index. warren myers with us. he's keeping an eye on the charts for any signals of a pullback. warren, good to see you. thank you for joining us. >> good to be here. >> tech is where the money has been moving. what do you see? >> we've had a very strong first of the year in tech. it's outperformed by far. it caught up from last year, and went forward. the big names, best of breeds, apples, microsofts, ibms have all performed very well. that's where it's pulling a

seema mody's been following it. what can you tell us? >> another day and another recall for johnson & johnson. today recalling about a half million one-ounce bottles of infant tylenol after receiving complaints from parents that the container was difficult to use. guys, this isn't the first round of recalls. let's actually take a walk down history lane. we have composed a couple recalls that johnson & johnson has actually faced in 2012 as well as throughout 2011. so today this was the recall that was announced. in december though j & j recalled mote rin. two months before that recalls 200,000 syringes of its anemia drug. concerns there about poet ten si. in august removed about 2.5 million packages of tylenol cold multisymptom gel caps. and in june 2011 pulled 60,000 bottles of tylenol in the u.s. the reason there smelly odor. some compared to the lacquer put on wooden palettes. the rise in recalls poses several questions. is the fda approving drugs too quickly? is enough testing being done prior to being sold at the local pharma pharmac

back over to you. >> seema, thanks so much.ven weiss, you know, none of these companies want to go out and say directly, because none of them comment on rumor and speculation or any of that nonsense that's in the market yet, they'll all probably admit that they all have to be keeping their eye on the deal ball. >> well, without a doubt. and i've been involved in the biotech space for a very long time. i've seen some of the best biotech investors get blown up. so i would say that if an individual wants to own these stocks, they've got to own a basket. and further qualify that basket, you've got to own a bunch of pep-c stocks. even the ones that may make the first goal in getting past the fda, there may be another goal that they've got to hit and they're not going to get there. i like the wig stocks. there's no doubt pharma is going to continue to acquire biotech companies but they're going to buy bigger companies where it can move the needle in terms of products. so just be very cautious on the space. >> just to echo that. this

. >>> moving to the pharma beat, we have seema mody talking jane j. recalls of iconic brand tylenol battered reputation and facing intense generic competition and stock gone nowhere over the past five years. can j & j's new ceo turn it around? talk about a long and winding road for them. >> it surely has been a winding road for the company. first priority for the company is to fix some of these glaring problems. they're dealing with manufacturing errors, ongoing supply chain issues and that all led to a series of recalls as you can see right here. now i've been speaking to analyst who is have covered this company since the news broke. overall a positive reaction to welden stepping down. and most thinking alex is up to the challenge. he's actually the 411 on the new face of j & j. he's a former army captain joined as a sales rep in '88. switched over in 2004 to head the north american pharmaceutical business and then returned to j & j. the question is will his top priority be? one can only speculate, but first it's pretty obvious no more recalls. fix t

seema mody is up now. she's joining us from the nasdaq -- or actually the realtime exchange.hind me. >> let's reset the markets. concerns over greece definitely weighing on our u.s. major indices. we have the dow witness triple digit losses. the s&p down 10 points. and the nasdaq down .7%. remember, it's been technology that's been the bright spot for this year and for the year currently down 21 points for the nasdaq. taking a look at our fear index, it's up right now 9.5%. the highest level year-to-date at 20. also seeing money flow out of commodities. take a look at oil trading at $98 a barrel. and gold also witnessing pressure. taking a look at some of our winners and losers on the s&p 500. take a look at shares of salesforce.com currently up 2% surging on a batch of analyst reports saying the company closed some significant deals. on the losing side, gamestop and first solar getting hammered. further project delays. and gamestop lowered by 4.5% sinking on weak sales data. and netapp down 4.4% ahead of earnings. look at movers and shakers. let's also look at gold and other

i'm seema mody. time for three stocks in 30 seconds.ith the most active stock here at the nasdaq. that's dendreon. roesh extended tender offer but did not raise its bid. aillumina replying back saying the offer does not reflect the unique leadership position. and vivus climbing telling the company fda approval by april 16th. tyler, back to you. >> a lot of drug stocks in the news. seema, thank you very much. looks like silence is golden. "the artist" coming up big, but moneyball struck out. does an oscar win translate into big money? here to talk about that and more is julia boorstin in los ange s angeles. i think of the best picture nominees only "the help" was over $100 million in the box office. is that going to propel the winners to make more money? >> tyler, the answer is yes. but not a huge amount more. in general winning an award and specifically best picture does generate higher returns at the box office and higher home video sales. on average the films that won best picture over a 10-year period brought home an average of their

for now, tyler, over to you. >> seema, thank you very much. the markets sort of struggling a little bit today. make no mistake, the dow is in rally mode recovering very nicely from the march 2009 lows up nearly 100% in that period of time, three years. in fact, all three major indexes charging to the upside over the past few months now in bull-market territory since october of last year, each up more than 20%. so much green on the board that blackrock's chief said today he thinks investors should be 100% in stocks. should investors be as bullish as mr. fink and go all in, or is there reason to be cautious? and joining us is another larry, managing partner with may flower advisors. larry, let me start with you. you are, you say, becoming increasingly bullish. and one of the areas that you like, low and behold, is european multinationals. a lot of people would say what are you nuts? make your case, larry. >> yeah, larry fink has the right idea here. we know he's on the right track. maybe it's not 100% stocks for all investors, but we know stocks

tyler, back to you. >> seema, thank you very much. our power player today is one busy guy.rogers. not only does he manage the four-star rated t. rowe price equity income fund but he's chief investment officer of t. rowe price. he joins us today from t. rowe's headquarters in baltimore. brian, good to have you back. i'm having a little hard time hearing brian. i'm going to forge right ahead and assume that the viewers can hear you. i want to talk first about a subject that may be a little stray for a guy who manages an equity fund but is certainly top of mind for an awful lot of investors and that is the proposed changes that the s.e.c. may well mandate in money market mutual funds, a kind of fund that virtually all investors have one way or another. what do you think of those proposed changes number one? and do you think they are necessary? and will they make those funds safer? [ technical difficulties ] >> i guess we don't have brian's mic right now. let's see what we can do -- >> let's tell them what's coming up tomorrow. we have our power player tomorrow and hopefully we

this would seema lot easier considering the jobless rate is dropping. nevertheless -- many graduates have the rigt tools ... but findingthe right opportunities is still tough. ">>>students n s-s-u campus make their way to class in hopes of gadai and pursui a career. but for most it's not that easy. getting a degree isn guarantee for students to get into the career they worked toward in school mny student can't find jobs that relate to heir degrees and have to settle for jobs in any field. "for me it will be easy becae of my major, but other people in the business i don't think it will be as easy because there is still a decline he recession" the job market may b filled with jobs but caeers ar what students are striving for finding a caeer and not st another job is not something students have to do on their own. the s-j-s-u career center holds job fairs and prepares students by helping with resumes, propr attire, and job interview skils. "in two in a half weekse have the largest job fair of the whole semester coming up. 1-hundred-1employers coming as of

. >>> i'm seema mody. upbeat corporate earnings with the notable exception of amazon.com. seagate technologies, one of the wincers on the nasdaq 100. the management saying their customers are basically willing to pay more for the product because they want to avoid any risk of not getting enough supply of hard disk drives. the company's forecast alleviating concerns about seagate's business being damaged by the flooding in thailand. upgrading the stock from buy to hold. on the move, take a look at broadcom despite weakness in europe. the chipmaker beat the street with the quarterly numbers. the mobile computing number being the key driver there. qualcomm rising higher after hours. maria, back over to you. >> the "countdown" is on to facebook's ipo filing that could happen any now. julia, we hear you've got an exclusive sneak peek of the inner workings of facebook. tell us about it. >> i did, maria. it looked like a pretty boring corporate office here. but it's very cool inside. all exposed, you know, steel beams and unfinished wood and concrete floors. i hear that mark zuck

. >>> i'm seema mody with your market wrap. the dow rises 46. it nears the 13,000 level.e nasdaq loses. consumer prices rose last month as gas and food costs were higher. camp bell's soup was up thanks to better than expected earnings. and yelp is slated to go public with 7 million shares priced between $12 and $14 a share. that's it from cnbc. now back to "hardball." >>> welcome back to "hardball." it looks like mitt romney is engaged in a high-risk strategy as he fights to win the first of his many home states. michigan, romney has taken every opportunity he can to start bashing the labor unions out there. here are a few of his recent jabs. let's watch him. >> i have taken on union bosses before. i'm happy to take them on again, because i happy to believe you can protect the interests and a great industry like automobiles without having to give in to the auw. >> some of the union bosses get things wrong. i'm concerned when i watch a president kowtow to the union bosses by putting in place the labor that stopped the boeing decision. >> let's make sure we have not crow kn

thanks a lot, seema. >>> priceline is trading at highs not seen since july 1999.ng off a blowout fourth quarter at a 66% boost in its earnings. justin patterson joins us. justin, can it go even further than this? >> we think so. our price target was raised to $730 today. >> why? >> priceline has the best international exposure in the group. it grew about 78% last year. we think it can grow 30% over the next three years. >> it's got competitors like expedia and orbitz? >> priceline has done a good job securing the western europe market and extending its presence into asia and now latin america. if you look at a market like western europe, it's a lot more fragmented than the domestic market which is really chain dominated. priceline has a tremendous edge in terms of the number of hotels there. at the end of last quarter, priceline had 195,000 globally. that's multiples greater than any of its xet zblerz what are t -- >> what are the risks to your target? >> we saw pressure from thailand floods but priceline grew through it. europe is a little bit of a fear point rig

. >>> i'm seema mody with your market wrap. the s&p adds three. the nasdaq gains three.mates. disney reported profits better than expected. but shares were off more than 1% off hours. a shakeup at yahoo has four board members announcing their departures. that's it from cnbc. now back to "hardball." >>> a romney nomination would not be in the best interest of us winning the general election. we need to have a conservative alternative. and my feeling is that speaker gingrich has had his chance in the arena and came up short in florida and nevada. and now it's our turn hopefully to get a one on one in missouri, which we have. >> welcome back to "hardball." that was rick santorum last night going after his republican rivals mitt romney and newt gingrich. there are three republican races today. minnesota, colorado, and missouri. santorum is trying to portray himself as the conservative alternative. the romney campaign has taken time to criticize santorum. so just what threat does santorum pose at this point? does he really have a chance to knock off romney? recently endorsed

i'm seema mody. three stocks on our radar here. at micron tech, up better than 5.5%, expanding their joint venture with intel. the deal calls for micron to supply chips to intel. also on the move, take a look as shanghai listed sina corporation, their twitter service, weibo, will boost the second half. and priceline delivering an upbeat q1 guidance. the stock outperforming in today's trading session. >>> time is the biggest ally when it comes to retirement savings. if you're part of a growing population that needs to catch up, postponing your retirement by just three years may be the easiway to go. sharon epperson takes a deep dive on the ways to catch up. i'm listening, sharon. >> all right, sue. the h.r. consulting firm towers watson did a survey and found that 39% of workers plan to delay retirement. now, the findings in this survey mirrored what we found when we talked to a roundtable of financial experts. that is, for those delaying retirement, they plan to work an extra three years. >> if you have a job. i think part of this

. >>> i'm seema mody with your market wrap. the s&p is off half a point. the nasdaq is lower by 3.uilding. and boeing shares sank 1% after it said dream liners need repairs. that's it from cnbc first in business worldwide. now back to "hardball." >>> welcome back to "hardball." the economy is expected to be the main issue. there are several major flash points in the world that will affect the economy. they are in the middle east now. look at what the president is facing right now. just recent days, on syria, russia and china vetoed a resolution that would have called on assad to step down. the united states closed their embassy in demascas. they are on shaky ground after officials said 19 americans connected with the prodemocracy citizens. one is sam lahood. and most troubling, israeli leaders continuing to hint that military action by them is coming against iran. could that be an october surprise? the chief washington correspondent for "the new york times" joins us. david, let's go through the relatively easy. syria, why are we worried about so much? >> this has been a huge humani

let's check in with cnbc's seema mody. she joins us with the day's business headlines. >> hi, barbara. stocks opened higher, but pretty flat. news from europe continues to take its toll on our u.s. markets. greece's government said it was preparing an agreement on a $130 billion euro bailout that will be put to the nation's leaders later in the day. now, this delay in formulating a deal is keeping investors at edge, and thus the reason we're seeing some consolidation in our u.s. markets. nonetheless, though, u.s. majorin did he sees still up for the year. the nasdaq up 9% for year-to-date for 2012 and the dow up similarly, up 5%. in terms of stories we're following today, gasoline prices are hovering around a record high. in the month of january, retail gasoline prices averaged at $3.37 a gallon. this new record means more pain in american budgets. a typical household burning 50 gallons of gasoline a month paid $168 168.50 for that fuel in january or $33 more than in january of 2010. >>> in other news, federal reserve chai

i'm seema mody. time for three stocks in 30 seconds. let's start with novo, the world's largest insulin maker stock up 4%. moving onto merck, they also reported a profit of 97 cents a share, two cents higher than analyst projections. why is the stock down? guidance came shy of street expectations as they expect to lose sales to competitors once the number one drug goes off patent. and gilliad sciences, topic of conversation on the call will certainly be $11 billion acquisition of pharma asset and when they plan to launch the hepatitis c drug. >>> lawmakers holding hearings today on capitol hill about the collapse of mf global. this time they're focusing on the role of risk managers at the business. kayla tausche has the latest. >> simon, at this moment we have the reps from moody's and s&p testifying. they're in the thick of it. after this morning mf's former risk chiefs were grilled on the missing money. their answer they don't know and had nothing to do with that. but there was some familiar territory like whether mf global purposely

good evening, seema. >> that's right, facebook's initial public offering may value mark zuckerburg at $15 billion. that may make him on par with ellison who started oracle 35 years ago. not bad. and the world's largest diversified commodities trader is in talks to buy a mining group in a transaction that could combine close to $80 billion. the merger would create one of the world's largest mining companies. >>> and china snaps up three energy deals. chinese institutions unveil three separate energy deals in north america and europe that underscore beijing's need to seed its booming economy. >>> and potentially bad news for pfizer, recalled birth control pills could spur big losses for the birth control giant. it's possible women who become pregnant after taking the def t defective pills could sue pfizer for unwanted pregnancies. so-called wrongful pregnancy cases similar to medical malpractice. >>> and turning to news overseas, thousands clash in cairo and other egyptian cities following the deaths of at least 73 people after a soccer brawl in the city. last night's brawl was the bloo

. >>> 'em seema moddy with your cnbc market wrap.3,000, the s&p off six and the nasdaq topped 3,000 but ended the day down 0 points. stocks slid on comment from bank of america saying unemployment would continue to fall unless growth picked up. the beige book said the economy saw modest growth in recent weeks. gas prices up for another 22nd day in a row, up 30 cents in the past month. that's it from cnbc. first business worldwide. now back to "hardball." >> when will my colleagues understand this very nondebatable fact? that the decision of weather a woman takes one medicine or another or what type of health care she should have access to should not be the decision of her boss. >> welcome back to hardball. that's the new york senator previewing the fight to come tomorrow when the senate votes on legislation sponsored by missouri republican roy blunt that would let anyone, employee or employer, opt out of pars of the health care plan inconsistent with their religious beliefs or their own moral convictions. this gets to the heart of th